Delayed Clinical Response in Patients with Juvenile Idiopathic Arthritis Treated with Etanercept

Marieke H. Otten; Femke H. M. Prince; Marinka Twilt; Marion A. J. van Rossum; Wineke Armbrust; Esther P. A. H. Hoppenreijs; Sylvia Kamphuis; Yvonne Koopman-Keemink; Nico M. Wulffraat; Simone L. Gorter; Rebecca ten Cate; Lisette W. A. van Suijlekom-Smit

doi:https://doi.org/10.3899/jrheum.090550

Delayed Clinical Response in Patients with Juvenile Idiopathic Arthritis Treated with Etanercept

Marieke H. Otten, Femke H. M. Prince, Marinka Twilt, Marion A. J. van Rossum, Wineke Armbrust, Esther P. A. H. Hoppenreijs, Sylvia Kamphuis, Yvonne Koopman-Keemink, Nico M. Wulffraat, Simone L. Gorter, Rebecca ten Cate, Lisette W. A. van Suijlekom-Smit

Research output: Contribution to journal › Article › Academic › peer-review

6 Citations (Scopus)

Abstract

Objective. To evaluate response in patients with juvenile idiopathic arthritis (JIA) who failed to meet response criteria after 3 months of etanercept treatment. Methods. This was a prospective ongoing Multicenter observational study of all Dutch patients with JIA using etanercept. Response according to American College of Rheumatology Pediatric 30 criteria was assessed at study start and at 3 and 15 months. Results. In total we studied 179 patients of median age 5.8 years at disease onset; 70% were female. Thirty-four patients did not respond after 3 months, of which 20 continued etanercept and 11 achieved response thereafter. Conclusion. The delayed clinically relevant response in a substantial proportion of patients who initially did not respond justifies the consideration of continuing therapy to at least 6 months. (First Release Jan 15 2010; J Rheumatol 20 10;37:665-7 doi: 10.3899/jrheum.090550)

Original language	English
Pages (from-to)	665-667
Journal	Journal of rheumatology
Volume	37
Issue number	3
DOIs	https://doi.org/10.3899/jrheum.090550
Publication status	Published - 2010

Access to Document

https://doi.org/10.3899/jrheum.090550

Cite this

Otten, M. H., Prince, F. H. M., Twilt, M., van Rossum, M. A. J., Armbrust, W., Hoppenreijs, E. P. A. H., Kamphuis, S., Koopman-Keemink, Y., Wulffraat, N. M., Gorter, S. L., ten Cate, R., & van Suijlekom-Smit, L. W. A. (2010). Delayed Clinical Response in Patients with Juvenile Idiopathic Arthritis Treated with Etanercept. Journal of rheumatology, 37(3), 665-667. https://doi.org/10.3899/jrheum.090550

@article{61dd9ee87cb3474c9f2fd802319be7f0,

title = "Delayed Clinical Response in Patients with Juvenile Idiopathic Arthritis Treated with Etanercept",

abstract = "Objective. To evaluate response in patients with juvenile idiopathic arthritis (JIA) who failed to meet response criteria after 3 months of etanercept treatment. Methods. This was a prospective ongoing Multicenter observational study of all Dutch patients with JIA using etanercept. Response according to American College of Rheumatology Pediatric 30 criteria was assessed at study start and at 3 and 15 months. Results. In total we studied 179 patients of median age 5.8 years at disease onset; 70% were female. Thirty-four patients did not respond after 3 months, of which 20 continued etanercept and 11 achieved response thereafter. Conclusion. The delayed clinically relevant response in a substantial proportion of patients who initially did not respond justifies the consideration of continuing therapy to at least 6 months. (First Release Jan 15 2010; J Rheumatol 20 10;37:665-7 doi: 10.3899/jrheum.090550)",

author = "Otten, {Marieke H.} and Prince, {Femke H. M.} and Marinka Twilt and {van Rossum}, {Marion A. J.} and Wineke Armbrust and Hoppenreijs, {Esther P. A. H.} and Sylvia Kamphuis and Yvonne Koopman-Keemink and Wulffraat, {Nico M.} and Gorter, {Simone L.} and {ten Cate}, Rebecca and {van Suijlekom-Smit}, {Lisette W. A.}",

year = "2010",

doi = "https://doi.org/10.3899/jrheum.090550",

language = "English",

volume = "37",

pages = "665--667",

journal = "Journal of rheumatology",

issn = "0315-162X",

publisher = "Journal of Rheumatology",

number = "3",

}

Otten, MH, Prince, FHM, Twilt, M, van Rossum, MAJ, Armbrust, W, Hoppenreijs, EPAH, Kamphuis, S, Koopman-Keemink, Y, Wulffraat, NM, Gorter, SL, ten Cate, R & van Suijlekom-Smit, LWA 2010, 'Delayed Clinical Response in Patients with Juvenile Idiopathic Arthritis Treated with Etanercept', Journal of rheumatology, vol. 37, no. 3, pp. 665-667. https://doi.org/10.3899/jrheum.090550

TY - JOUR

T1 - Delayed Clinical Response in Patients with Juvenile Idiopathic Arthritis Treated with Etanercept

AU - Otten, Marieke H.

AU - Prince, Femke H. M.

AU - Twilt, Marinka

AU - van Rossum, Marion A. J.

AU - Armbrust, Wineke

AU - Hoppenreijs, Esther P. A. H.

AU - Kamphuis, Sylvia

AU - Koopman-Keemink, Yvonne

AU - Wulffraat, Nico M.

AU - Gorter, Simone L.

AU - ten Cate, Rebecca

AU - van Suijlekom-Smit, Lisette W. A.

PY - 2010

Y1 - 2010

N2 - Objective. To evaluate response in patients with juvenile idiopathic arthritis (JIA) who failed to meet response criteria after 3 months of etanercept treatment. Methods. This was a prospective ongoing Multicenter observational study of all Dutch patients with JIA using etanercept. Response according to American College of Rheumatology Pediatric 30 criteria was assessed at study start and at 3 and 15 months. Results. In total we studied 179 patients of median age 5.8 years at disease onset; 70% were female. Thirty-four patients did not respond after 3 months, of which 20 continued etanercept and 11 achieved response thereafter. Conclusion. The delayed clinically relevant response in a substantial proportion of patients who initially did not respond justifies the consideration of continuing therapy to at least 6 months. (First Release Jan 15 2010; J Rheumatol 20 10;37:665-7 doi: 10.3899/jrheum.090550)

AB - Objective. To evaluate response in patients with juvenile idiopathic arthritis (JIA) who failed to meet response criteria after 3 months of etanercept treatment. Methods. This was a prospective ongoing Multicenter observational study of all Dutch patients with JIA using etanercept. Response according to American College of Rheumatology Pediatric 30 criteria was assessed at study start and at 3 and 15 months. Results. In total we studied 179 patients of median age 5.8 years at disease onset; 70% were female. Thirty-four patients did not respond after 3 months, of which 20 continued etanercept and 11 achieved response thereafter. Conclusion. The delayed clinically relevant response in a substantial proportion of patients who initially did not respond justifies the consideration of continuing therapy to at least 6 months. (First Release Jan 15 2010; J Rheumatol 20 10;37:665-7 doi: 10.3899/jrheum.090550)

U2 - https://doi.org/10.3899/jrheum.090550

DO - https://doi.org/10.3899/jrheum.090550

M3 - Article

C2 - 20080910

SN - 0315-162X

VL - 37

SP - 665

EP - 667

JO - Journal of rheumatology

JF - Journal of rheumatology

IS - 3

ER -